Dykellic acid (C 14 H 16 O 4 ) is a novel compound initially isolated from the culture broth of Westerdykella multispora F50733.
Invasion Assay Transwell plates (pore size 8 mm; Costar, NY, U.S.A.) were loaded with 100 ml Matrigel (BD Biosciences, NJ, U.S.A.), which was allowed to solidify at 37°C for 2 h and then coated with 10 ml fibronectin (200 mg/ml). The plates were loaded with B16 cells suspended in 10% FBS (1ϫ10 5 cells/well), the samples were exposed to dykellic acid at a final concentration of 0 or 50 mM, and the plates were incubated at 37°C in 5% CO 2 for 24 h. The migrated cells were fixed with methanol, stained with hematoxylin, and counted under a microscope. 13) Tube Formation Assay HUVECs (2ϫ10 4 cells/well) were dispensed to Matrigel-coated 24-well plates in 0.5 ml of EGM-2 containing various concentrations of dykellic acid (0 Dykellic acid, a novel factor initially identified from the culture broth of Westerdykella multispora F50733, has been shown to inhibit matrix metalloprotease 9 activity, caspase-3 activity, B cell proliferation and LPS-induced IgM production, suggesting that this factor may have anti-cancer effects. In an effort to further address the possible anti-tumoral effects of dykellic acid, we used wound healing, invasion and RhoA-GTP assays to examine the effects of dykellic acid on cell migration, invasion and angiogenesis. Our results revealed that dykellic acid dose-dependently inhibits B16 cell migration and motility, and inhibits HUVEC tube formation. Western blot analysis of the active form of RhoA (RhoA-GTP) showed that dykellic acid treatment decreased the levels of RhoA-GTP. These findings collectively suggest that dykellic acid may have both anti-metastatic and antiangiogenic acitivites, and provides the first evidence for the involvement of RhoA in dykellic acid-induced effects.
Dykellic Acid Inhibits Cell Migration and Tube Formation by RhoA-GTP Expression
or 50 mM), and incubated for 24 h. The cells were then visualized by microscopy and tube formation was scored by counting the tube formed or not. 14) Western Blot Analysis RhoA activity was assessed using a RhoA-GTP Kit (Pierce, Rockford, IL, U.S.A.), according to the manufacturer's instructions. Briefly, B16 cells (1ϫ10 6 cells) were centrifuged at 16000ϫg. The supernatant (cell lysate) was incubated for 1 h at 4°C with the provided GST-Rhotekin-RBD, and then 25 ml/lane was loaded onto a SwellGel immobilized glutathione disk (Pierce, Rockford, IL, U.S.A.) The glutathione disk-bound proteins were solubilized with 2ϫSDS [125 mM Tris-HCl, pH 6.8, 2% glycerol, 4% SDS (w/v), 0.05% mercaptoethanol, and 0.05% bromophenol blue], eluted from the disk, resolved by 12% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were blocked for 1 h with Tween (0.1%)/TBS and incubated with the primary antibody (Pierce, Rockford, IL, U.S.A.). The results were detected with an HRP-conjugated secondary antibody (Pierce, Rockford, IL, U.S.A.) and visualized with an ECL detection system (Amersham Pharmacia Biotech, Buckinghamshire, U.K.).
12)
Statistical Analysis Data were expressed as the meanϮstandard deviation of the mean values. Statistical significance was determined by Student-Newman-Keuls method for independent means, using the Sigma Plot program. The critical level for significance was set at p<0.05.
RESULTS AND DISCUSSION
Dykellic acid, a novel compound initially identified from a culture broth of Westerdykella multispora F50733, has been shown to inhibit MMP9 activation and caspase-3 protease activity, and also appears to have immunosuppressive effects. [2] [3] [4] Because MMP9 and caspase-3 are associated with cancer promotion, we question whether dykellic acid affect cell motility and invasion, two major hallmarks of angiogenesis. 15) Therefore, we first examined the motility of dykellic acidtreated B16 cells. We used wound healing and invasion assays to test the in vitro effect of dykellic acid on cell migration, which is an important facet of cell motility, particularly in relation to cancer. Our wound healing assay revealed that while untreated control monolayers showed complete wound healing within 48 h, monolayers treated with 50 mM dykellic acid showed clear wound width, suggesting that dykellic acid inhibit cell migration in vitro in a dose-dependent fashion (Fig. 1A) . Interestingly, PMA-treated monolayers showed also strong cell growth inhibitory pattern as control did, sug- gesting that dykellic acid inhibited cell migration activity with or without cell proliferation inducer. Similarly, our invasion assay revealed that 50 mM dykellic acid inhibited invasive activity by more than 80% versus the control group (Fig.  2) . These results indicate that dykellic acid dose-dependently inhibits wound healing and inhibits invasion in vitro.
Next, we examined the effect of dykellic acid on angiogenesis, which is a second critical component of metastasis. HUVECs were treated with and without various concentrations of dykellic acid, and tube formation was assessed in terms of tube size and number. Our results revealed that dykellic acid dose-dependently inhibited HUVEC tube formation in vitro at 0 to 100 mM (Fig. 3) . The results revealed that the untreated controls showed the highest levels of proliferation, indicating that endothelial cell growth was not restricted by contact inhibition under our experimental conditions. 7) Collectively, these findings indicate that dykellic acid inhibits cell migration, cell invasiveness and tube formation in vitro, suggesting that this factor might function as an anti-tumoral agent in vivo by decreasing metastasis and angiogenesis.
Lastly, we investigated the effect of dykellic acid on the levels of its potential signaling partner, RhoA. Signal transduction during angiogenesis is fairly well understood. Many transcription factors (e.g. EST-1, c-Fos and c-jun) and migration-related proteins are associated with gene expression in endothelial cells (ECs) during angiogenesis. 16) VEGF acts as a central regulator, while many morphological changes are overseen by members of the Rho protein family of GTPases.
These GTPases mediate cell contractility by organizing actin filaments into stress fibers, 17, 18) thereby influencing the motility and migration of ECs, as well as the formation of new blood vessels. Therefore, we examined the effect of dykellic acid on RhoA-GTP levels in B16 cells. Our Western blot analysis revealed that treatment of cells with 50 mM dykellic acid inhibited RhoA-GTP activity to approximately 50% (Figs. 4A, B) , suggesting that dykellic acid have potential to decrease the active form of RhoA rather than the activity level per se. Not only other GTPases (such as Cdc42, Rac1), but also cancer-related molecules (CD44, Timp-1, Timp-2, Paxillin, Src, and MMP-14) did not change in its expression level by dykellic acid (data not shown), although the precise up-and down-stream signal transduction pathway need to be understood.
In sum, we herein show for the first time that dykellic acid dose-dependently inhibits B16 cell migration and motility, and inhibits HUVEC tube formation in vitro, resulting in decreasing the levels of RhoA-GTP. These findings, in combination with previous reports indicating dykellic acid inhibits not only caspase-3-like protease activation, but also PMA-induced increase in MMP-9 expression, suggest that dykellic acid should be considered a promising candidate for future development as a possible anti-cancer agent. through Grape Research Projects Group on anticancer in vitro assays.
